Table 1 Overview of studies
Study (location) | N | Study details | Population | Age (years) | Sex (% males) | Major endpoints | FU (lost to FU) |
|---|---|---|---|---|---|---|---|
635 | Controlled trial comparing short- and long-term flecainide therapy after cardioversion in patients with persistent AF | AF | 18–89 | 66% | Recurrent AF. MACE events centrally adjudicated and available. | 6 months | |
AFCT (Netherlands) | 388 | Observational: Retrospective, case-control | SR, AF | 23–74 | 68% | MACE | 2–3 years |
BBC-AF (United Kingdom) | 1632 | Registry | SR, AF | 20–97 | 60% | MACCE. Recurrent AF is captured clinically | 2 years |
FUTURE (Spain) | 198 | Registry | SR, AF | 22–60 | 85% | Retrospective follow-up (clinical AF recurrence/incidence) | 4–5 years |
RACE IV (Netherlands) | 1370 | Controlled trial of “holistic” AF management and usual care, recently detected AF | AF | 19–89 | 66% | MACE, recurrent AF, AF progression | 2–3 years |
MULTIAF (Netherlands) | 70 | Observational: Prospective | AF | 33–83 | 77% | Recurrence of persistent AF | 6 months |
READ-POAF (Netherlands) | 79 | Observational | SR | 42–84 | 73% | Incident AF, MACCE | 3 years |
Tissue bank | 246 | Combined tissue bank | AF | 20–85 | 70% | Tissue characteristics, no specific follow-up | Variable |
AFLMU (Germany) | 3573 | Ongoing registry of AF patients from a large arrhythmia clinic | AF | 16–93 | 69% | Recurrent AF following intervention (Follow-up available for part of the cohort) | ongoing. Median 1 year FU |
KORA (Germany) | 4279 | Population-based survey including digital ECG, biosamples and detailed characterization | SR | 25–74 | 49% | Incidence of death, stroke, and myocardial infarction | Ongoing since enrolment |
GIRAFA [52] (Spain) | 210 | Patients with lone AF | AF | 18–70 | 70% | Retrospective follow-up | Mean 9 years (AF patients) |
PVIBCN [53] (Spain) | 1088 | Cohort of patients undergoing AF ablation | AF | 19–79 | 74% | Ongoing, systematic follow-up for AF recurrence. | 1–2 years |